AGA2118 clinical trials
Also written AGA2118.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2022
How each study uses AGA2118 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- AGA2118
- 3
Studies by the year they started
3 studies that test it; most in 2022 (1)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Angitia Biopharmaceuticals (2) · Angitia Incorporated Limited (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test AGA2118.
- Dec 2026A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS)Phase 2 · Angitia Biopharmaceuticals
Studies
Open first, then newest update. How each study uses AGA2118 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- An Ethnobridging TriaL of AGA2118 in Healthy Japanese, Chinese, and Caucasian ParticipantS (ATLAS)CompletedPhase 1Angitia Incorporated LimitedNCT07361354Written as AGA2118
- A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS)Active, not recruitingPhase 2Angitia BiopharmaceuticalsNCT06577935Written as AGA2118
- A First-in-Human Study Evaluating AGA2118 in Men and Postmenopausal WomenCompletedPhase 1Angitia BiopharmaceuticalsNCT05225857Written as AGA2118